A citation-based method for searching scientific literature

Klara R Klein, Jennifer L R Freeman, Imogene Dunn, Chris Dvergsten, M Sue Kirkman, John B Buse, Carmen Valcarce. Diabetes Care 2021
Times Cited: 4







List of co-cited articles
2 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study.
Dalong Zhu, Shenglian Gan, Yu Liu, Jianhua Ma, Xiaolin Dong, Weihong Song, Jiao'e Zeng, Guixia Wang, Wenjuan Zhao, Qiu Zhang,[...]. Lancet Diabetes Endocrinol 2018
24
50



Years of potential life lost in pre-diabetes and diabetes mellitus: data from a 40-year follow-up of the Israel study on Glucose intolerance, Obesity and Hypertension.
Micha Rapoport, Angela Chetrit, Dror Cantrell, Ilya Novikov, Jesse Roth, Rachel Dankner. BMJ Open Diabetes Res Care 2021
2
50

Global prevalence of metabolic syndrome among patients with type I diabetes mellitus: a systematic review and meta-analysis.
Rebuma Belete, Zerihun Ataro, Ahmedmenewer Abdu, Merga Sheleme. Diabetol Metab Syndr 2021
8
25

Trends in the incidence of diagnosed diabetes: a multicountry analysis of aggregate data from 22 million diagnoses in high-income and middle-income settings.
Dianna J Magliano, Lei Chen, Rakibul M Islam, Bendix Carstensen, Edward W Gregg, Meda E Pavkov, Linda J Andes, Ran Balicer, Marta Baviera, Elise Boersma-van Dam,[...]. Lancet Diabetes Endocrinol 2021
19
25


Quantifying the Sex-Race/Ethnicity-Specific Burden of Obesity on Incident Diabetes Mellitus in the United States, 2001 to 2016: MESA and NHANES.
Natalie A Cameron, Lucia C Petito, Megan McCabe, Norrina B Allen, Matthew J O'Brien, Mercedes R Carnethon, Sadiya S Khan. J Am Heart Assoc 2021
4
25

GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis.
Thomas Karagiannis, Apostolos Tsapas, Eleni Athanasiadou, Ioannis Avgerinos, Aris Liakos, David R Matthews, Eleni Bekiari. Diabetes Res Clin Pract 2021
9
25


Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy.
Chintan V Dave, Seoyoung C Kim, Allison B Goldfine, Robert J Glynn, Angela Tong, Elisabetta Patorno. Circulation 2021
13
25

Risk Factors for Longitudinal Resting Heart Rate and Its Associations With Cardiovascular Outcomes in the DCCT/EDIC Study.
Sareh Keshavarzi, Barbara H Braffett, Rodica Pop-Busui, Trevor J Orchard, Elsayed Z Soliman, Gayle M Lorenzi, Annette Barnie, Amy B Karger, Rose A Gubitosi-Klug, Samuel Dagogo-Jack,[...]. Diabetes Care 2021
1
100

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
25

Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes.
Thomas Danne, Jeremy Pettus, Andrea Giaccari, Bertrand Cariou, Helena Rodbard, Stuart A Weinzimer, Mireille Bonnemaire, Sangeeta Sawhney, John Stewart, Stella Wang,[...]. Diabetes Technol Ther 2019
10
25

Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes.
Marc Evans, Debbie Hicks, Dipesh Patel, Vinod Patel, Phil McEwan, Umesh Dashora. Diabetes Ther 2020
16
25


Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m2.
Thomas Danne, Steven Edelman, Juan Pablo Frias, Francisco Javier Ampudia-Blasco, Philip Banks, Wenjun Jiang, Michael J Davies, Sangeeta Sawhney. Diabetes Obes Metab 2021
4
25

Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
786
25

Sotagliflozin added to optimized insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: A pooled analysis of inTandem1 and inTandem2.
Helena W Rodbard, Andrea Giaccari, Rosemarie Lajara, John Stewart, Paul S Strumph, Juliana Oliveira, Pablo Lapuerta, Rita Castro. Diabetes Obes Metab 2020
4
25


Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies.
Anne L Peters, Darren K McGuire, Thomas Danne, Jake A Kushner, Helena W Rodbard, Ketan Dhatariya, Sangeeta Sawhney, Phillip Banks, Wenjun Jiang, Michael J Davies,[...]. Diabetes Care 2020
7
25



Metabolic Control in Type 1 Diabetes: Is Adjunctive Therapy the Way Forward?
Harriet Warnes, Rebecca Helliwell, Sam Matthew Pearson, Ramzi A Ajjan. Diabetes Ther 2018
13
25

Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 Trials.
Paolo Pozzilli, Richard D Leslie, Anne L Peters, Raffaella Buzzetti, Sudha S Shankar, Zvonko Milicevic, Imre Pavo, Jeremie Lebrec, Sherry Martin, Nanette C Schloot. Diabetes Obes Metab 2018
21
25


Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
25

Dipeptidyl peptidase 4 inhibitor sitagliptin maintains β-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study.
Yunjuan Zhao, Lin Yang, Yufei Xiang, Lingjiao Liu, Gan Huang, Zhaofeng Long, Xia Li, R David Leslie, Xiangbing Wang, Zhiguang Zhou. J Clin Endocrinol Metab 2014
77
25


Role of Amylin in Type 1 and Type 2 Diabetes.
Laura Hieronymus, Stacy Griffin. Diabetes Educ 2015
26
25

Non-insulin pharmacological therapies for treating type 1 diabetes.
Christian Seerup Frandsen, Thomas Fremming Dejgaard, Sten Madsbad, Jens Juul Holst. Expert Opin Pharmacother 2018
6
25

Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.
John B Buse, Satish K Garg, Julio Rosenstock, Timothy S Bailey, Phillip Banks, Bruce W Bode, Thomas Danne, Jake A Kushner, Wendy S Lane, Pablo Lapuerta,[...]. Diabetes Care 2018
105
25

Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program.
Thomas Danne, Bertrand Cariou, John B Buse, Satish K Garg, Julio Rosenstock, Phillip Banks, Jake A Kushner, Darren K McGuire, Anne L Peters, Sangeeta Sawhney,[...]. Diabetes Care 2019
37
25

Adjunct therapy for type 1 diabetes mellitus.
Harold E Lebovitz. Nat Rev Endocrinol 2010
35
25

Beyond glycaemic control: A cross-over, double-blinded, 24-week intervention with liraglutide in type 1 diabetes.
Marie-Christine Dubé, Martin D'Amours, S John Weisnagel. Diabetes Obes Metab 2018
15
25

Type 1 diabetes.
Mark A Atkinson, George S Eisenbarth, Aaron W Michels. Lancet 2014
25

The mechanisms of action of metformin.
Graham Rena, D Grahame Hardie, Ewan R Pearson. Diabetologia 2017
751
25

Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus.
Christian Seerup Frandsen, Thomas Fremming Dejgaard, Sten Madsbad. Lancet Diabetes Endocrinol 2016
50
25

Adjunctive therapy for glucose control in patients with type 1 diabetes.
Kira Harris, Cassie Boland, Lisa Meade, Dawn Battise. Diabetes Metab Syndr Obes 2018
10
25

Discovery, characterization, and clinical development of the glucagon-like peptides.
Daniel J Drucker, Joel F Habener, Jens Juul Holst. J Clin Invest 2017
140
25

Glucokinase Activators for Type 2 Diabetes: Challenges and Future Developments.
Konstantinos A Toulis, Krishnarajah Nirantharakumar, Chrysa Pourzitaki, Anthony H Barnett, Abd A Tahrani. Drugs 2020
24
25

Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial.
John R Petrie, Nishi Chaturvedi, Ian Ford, Martijn C G J Brouwers, Nicola Greenlaw, Therese Tillin, Irene Hramiak, Alun D Hughes, Alicia J Jenkins, Barbara E K Klein,[...]. Lancet Diabetes Endocrinol 2017
158
25

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study.
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Diabetes Care 2018
104
25

SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects.
Ele Ferrannini, Anna Solini. Nat Rev Endocrinol 2012
266
25

Insulin and Glucagon: Partners for Life.
Jens Juul Holst, William Holland, Jesper Gromada, Young Lee, Roger H Unger, Hai Yan, Kyle W Sloop, Timothy J Kieffer, Nicolas Damond, Pedro L Herrera. Endocrinology 2017
44
25

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial.
Chantal Mathieu, Paresh Dandona, Pieter Gillard, Peter Senior, Christoph Hasslacher, Eiichi Araki, Marcus Lind, Stephen C Bain, Serge Jabbour, Niki Arya,[...]. Diabetes Care 2018
127
25


Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: A randomized, placebo-controlled, double-blind, parallel-group study.
Christian S Frandsen, Thomas F Dejgaard, Henrik U Andersen, Jens J Holst, Bolette Hartmann, Birger Thorsteinsson, Sten Madsbad. Diabetes Obes Metab 2017
15
25

Metformin as add-on to intensive insulin therapy in type 1 diabetes mellitus.
Frederik Staels, Carolien Moyson, Chantal Mathieu. Diabetes Obes Metab 2017
16
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.